logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Niraparib for metastatic castration-resistant prostate cancer with DNA-repair anomalies

< Back

Niraparib for metastatic castration-resistant prostate cancer with DNA-repair anomalies

Drugs

Cancer and Palliative Care

February 2020


Niraparib is in clinical development for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) with DNA-repair anomalies. Prostate cancer is the most common type of cancer in men in the UK. The cancer is called advanced (metastatic) prostate cancer when the cancer cells have spread to other parts of the body like bones, lymph nodes outside the pelvis or rarely to the liver or lungs. It is not possible to cure metastatic prostate cancer but is possible to keep it under control. Prostate cancers that continue to grow despite hormonal therapies are called “castration-resistant” prostate cancer. In some mCRPC, mutations in several genes involved in DNA damage repair have been reported and treatments that target these DNA anomalies are being developed.
Niraparib is a medicinal product taken orally. It works by blocking a protein called poly (adenosine diphosphate-ribose) polymerase (PARP). It blocks the action of PARP-1 and PARP-2 enzymes that help in repairing damaged DNA in cells when they divide to make new cells. By blocking PARP enzymes, the damaged DNA in cancer cells cannot be repaired, and the cells die. If licensed, niraparib will offer an additional treatment option for men with mCRPC with DNA-repair anomalies.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Technology



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts